RU-0211
RU-0211 Brand names, RU-0211 Analogs
RU-0211 Brand Names Mixture
- No information avaliable
RU-0211 Chemical_Formula
C21H16ClF3N4O3
RU-0211 RX_link
No information avaliable
RU-0211 fda sheet
RU-0211 msds (material safety sheet)
RU-0211 Synthesis Reference
No information avaliable
RU-0211 Molecular Weight
464.825 g/mol
RU-0211 Melting Point
No information avaliable
RU-0211 H2O Solubility
Practically insoluble (as tosylate salt)
RU-0211 State
Solid
RU-0211 LogP
3.671
RU-0211 Dosage Forms
Tablets (oral, 200 mg)
RU-0211 Indication
For the treatment of patients with advanced renal cell carcinoma.
RU-0211 Pharmacology
Sorafenib is a multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinases. It is commonly available as a tosylate salt. Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib inhibits tumor growth of the murine renal cell carcinoma, RENCA, and several other human tumor xenografts in athymic mice. A reduction in tumor angiogenesis occurs in some tumor xenograft models.
RU-0211 Absorption
The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.
RU-0211 side effects and Toxicity
The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.
RU-0211 Patient Information
RU-0211 Organisms Affected
Humans and other mammals
